TMCnet News
Abzena plc full year results: revenues up 74%, strong outlook within growing marketAbzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2016. Corporate highlights
Financial summary
Ken Cunningham, Chairman of Abzena, commented: "Over the last 12 months, Abzena has been delivering on its growth strategy. This transformational year has seen the international expansion of the Group's operational footprint with the completion of two acquisitions in the US. The Group is now able to support its partners further through the drug development process and to position its technologies to a broader set of customers." John Burt, CEO of Abzena, commented: "Abzena is fast becoming a preferred partner for biopharmaceutical services. The integration of our businesses in the UK and US enables us to offer more services to a broader set of organisations and helps existing customers access the tools to translate their research into clinical products. We continue to focus on our growth strategy, investing in internal research & development to provide next generation technologies and enhancing our GMP manufacturing capabilities. ABZENA Inside partners and service customers alike are reacting very positively to our enlarged offering and we expect the number of opportunities to work on programmes across the Group to increase in the next financial year." For the full release, please visit the Group website at www.abzena.com. About Abzena Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups. The term ABZENA Inside is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ antibody drug conjugates. Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENA Inside products. Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
For more information, please see www.abzena.com View source version on businesswire.com: http://www.businesswire.com/news/home/20160613006593/en/ |